Experts Matter. Find Yours.
Connect for media, speaking, professional opportunities & more.
Manuka honey could help to clear deadly drug-resistant lung infection – research
• Scientists develop a potential nebulisation treatment using manuka honey to clear a drug resistant lung infection that can be fatal in cystic fibrosis patients • Aston University researchers combined the antibiotic amikacin with manuka honey as a novel treatment for Mycobacterium abscessus • Using the manuka honey combination resulted in an eight-fold reduction in the dosage of the antibiotic A potential new treatment combining natural manuka honey with a widely used drug has been developed by scientists at Aston University to treat a potentially lethal lung infection and greatly reduce side effects of one of the current drugs used for its treatment. The findings, which are published in the journal Microbiology, show that the scientists in the Mycobacterial Research Group in the College of Health and Life Sciences at Aston University were able to combine manuka honey and the drug amikacin in a lab-based nebulisation formulation to treat the harmful bacterial lung infection Mycobacterium abscessus. Manuka honey is long known to have wide ranging medicinal properties, but more recently has been identified for its broad spectrum antimicrobial activity. Now scientists have found that manuka honey has the potential to kill a number of drug resistant bacterial infections such as Mycobacterium abscessus – which usually affects patients with cystic fibrosis (CF) or bronchiectasis. According to the Cystic Fibrosis Trust, CF is a genetic condition affecting around 10,800 people - one in every 2,500 babies born in the UK -and there are more than 100,000 people with the condition worldwide. The NHS defines bronchiectasis as a long-term condition where the airways of the lungs become widened, leading to a build-up of excess mucus that can make the lungs more vulnerable to infection.. In the study, the researchers used samples of the bacteria Mycobacterium abscessus taken from 16 infected CF patients. They then tested the antibiotic amikacin, combined with manuka honey, to discover what dosage was required to kill the bacteria. As part of the study the team used a lab-based lung model and nebuliser - a device that produces a fine spray of liquid often used for inhaling a medicinal drug. By nebulising manuka honey and amikacin together, it was found they could improve bacterial clearance, even when using lower doses of amikacin, which would result in less life-changing side-effects to the patient. In the UK, of the 10,800 people living with CF, Mycobacterium abscessus infects 13% of all patients with the condition. This new approach is advantageous not only because it has the potential to kill off a highly drug resistant infection, but because of the reduced side effects, benefitting quality of life and greatly improving survival chances for infected CF patients. Mycobacterium abscessus is a bacterial pathogen from the same family that causes tuberculosis, but this bug differs by causing serious lung infections in people (particularly children) with pre-existing lung conditions, such as CF and bronchiectasis, as well as causing skin and soft tissue infections. The bacteria is also highly drug resistant. Currently, patients are given a cocktail of antibiotics, consisting of 12 months or more of antimicrobial chemotherapy and often doesn’t result in a cure. The dosage of amikacin usually used on a patient to kill the infection is 16 micrograms per millilitre. But the researchers found that the new combination using manuka honey, required a dosage of just 2 micrograms per millitre of amikacin - resulting in a one eighth reduction in the dosage of the drug. Until now Mycobacterium abscessus has been virtually impossible to eradicate in people with cystic fibrosis. It can also be deadly if the patient requires a lung transplant because they are not eligible for surgery if the infection is present. Commenting on their findings, lead author and PhD researcher Victoria Nolan said: "So far treatment of Mycobacterium abscessus pulmonary infections can be problematic due to its drug resistant nature. The variety of antibiotics required to combat infection result in severe side effects. "However, the use of this potential treatment combining amikacin and manuka honey shows great promise as an improved therapy for these terrible pulmonary infections. “There is a need for better treatment outcomes and in the future we hope that this potential treatment can be tested further.” Dr Jonathan Cox, senior lecturer in microbiology, Aston University said: “By combining a totally natural ingredient such as manuka honey with amikacin, one of the most important yet toxic drugs used for treating Mycobacterium abscessus, we have found a way to potentially kill off these bacteria with eight times less drug than before. This has the potential to significantly reduce amikacin-associated hearing loss and greatly improve the quality of life of so many patients – particularly those with cystic fibrosis. “I am delighted with the outcome of this research because it paves the way for future experiments and we hope that with funding we can move towards clinical trials that could result in a change in strategy for the treatment of this debilitating infection.” Dr Peter Cotgreave, chief executive of the Microbiology Society said: "The Microbiology Society is proud to support the scientific community as it explores innovative solutions to overcome the growing global challenge of antimicrobial resistance. This study demonstrates one of many ways in which microbiologists are pioneering new methods to tackle drug-resistant infections, by incorporating natural products, like manuka honey, into existing therapies." For more information about the School of Biosciences, please visit our website.
Researchers are exploring new ways to ‘listen’ to and record electrical signals emitted from brain cells Findings could be used to help treat conditions like epilepsy and schizophrenia Project will use newly developed nanomaterials to keep removed samples of brain healthy for longer to allow more understanding of what generates epileptic seizures. A new method of examining the brain’s electrical signals could hold the key to better treatment and understanding of conditions like epilepsy and schizophrenia. Researchers at Aston University are exploring new ways to ‘listen’ to and record electrical signals emitted from brain cells, which could be used to help treat the conditions. Dr Petro Lutsyk, lecturer in electronic engineering and systems in the College of Engineering and Physical Sciences and member of Aston Institute of Photonic Technologies (AIPT), together with Dr Stuart Greenhill, senior lecturer in neuroscience in the College of Health and Life Sciences and member of Aston Institute of Health and Neurodevelopment (IHN), have been awarded £100,000 by the Royal Society to conduct the project Nanomaterial Webs for Revolutionary Brain Recording. Currently, epilepsy patients who can’t be helped by drugs may undergo brain surgery in order to prevent seizures, removing the part of the brain that is the ‘focus’ of the seizures. Dr Greenhill said: “The research project will use newly developed nanomaterials to keep samples of brain healthy and active for far longer than current technology allows, whilst recording the activity of the tissue. “This allows more understanding of what generates epileptic seizures and opens up new avenues for drug development, meaning fewer surgeries may be needed in the future. “Eventually, the technology may lead to new and better ways of recording from patients’ brains before surgery.” The two-year project will see materials and electronic engineering applied to translational neuroscience research. The grant is from the Royal Society APEX Awards scheme (Academies Partnership in Supporting Excellence in Cross-disciplinary research award) which offers researchers with a strong track record in their area an opportunity to pursue interdisciplinary research to benefit wider society. For more information about studying at Aston University please visit our website.
ChristianaCare is out to revolutionize health care. One of the country’s most dynamic health care systems, ChristianaCare is partnering with two leaders in medical and therapy services to provide comprehensive, integrated virtual health services 24/7 to colleges, universities and other institutions of higher education. Together with PursueCare and SimpleTherapy, ChristianaCare created a bundled health care product that combines general medical services from ChristianaCare’s Center for Virtual Health, mental health and addiction treatment programs from PursueCare and hyper-personalized musculoskeletal care from SimpleTherapy. ‘The future of health care is virtual’ “At ChristianaCare, we know that the future of health care is virtual,” said Sharon Anderson, MS, RN, FACHE, ChristianaCare’s chief virtual health officer and president of ChristianaCare’s Center for Virtual Health. “When college students are able to access medical, behavioral health and musculoskeletal services through their phone or laptop, from their dorm room or a private space on campus, they’ll be more likely to get help when they need it. This is about delivering care to students on their terms, so that they can be healthy and supported with high-quality care throughout their college experience.” Personalized virtual health solutions will be available to students at participating higher education institutions through a customized portal accessible from any computer or mobile device. Students will be able to access assessments, resources and virtual treatment via modules or telemedicine sessions with licensed providers. The offering provides students with unlimited, on-demand care from a multidisciplinary team solving for a multitude of conditions. “For college and university student health services and administrators, this partnership offers a powerful new way to provide comprehensive, affordable health solutions that benefit students,” Anderson said. “In a highly competitive recruiting environment, these solutions are easy to implement and can add tremendous value. We are excited to partner with colleges and universities to strengthen their student health programs by creating a comprehensive virtual care solution to meet their student’s health care needs.” Through a single digital portal, participating students can access internal and family medicine providers from ChristianaCare’s Center for Virtual Health. PursueCare’s Joint Commission-accredited mental health, psychiatric and medication-assisted treatment providers, and SimpleTherapy’s licensed physical therapists specializing in musculoskeletal care, acute or chronic pain management, and strength and mobility training can all be accessed through the portal. Students will also have the option of using PursueCareRx for their pharmacy needs. PursueCareRx is a competitively priced full-service pharmacy that accepts most major insurance and delivers directly to customers. “Young adults face an escalating mental health and substance use crisis,” said Nick Mercadante, founder, and CEO of PursueCare. “Colleges and universities are frequently unable to comprehensively serve the increased need, and research suggests substance use, mental health and suicide carry a significant social stigma. Our goal is to work collaboratively with campus health resources to bring a low-barrier solution students can access privately, any time, on their terms. Additionally, partnering with a world-class health system like ChristianaCare means we can help support whole-person care needs.” “Chronic musculoskeletal disorders have never been more prevalent and traditional care pathways are often ineffective and costly,” said Arpit Khemka, co-founder and CEO of SimpleTherapy. "SimpleTherapy removes barriers for students allowing them to take control of their musculoskeletal health, reducing their need for high-cost, high-risk services, such as surgery and opioids, to manage pain. This results in higher compliance rates and more successful outcomes." Customized and co-branded product The product is designed for colleges, universities and all other higher education institutions. For a flat fee, a school will be able to offer care that is customized and co-branded with school-specific content to be an extension of existing campus health services. It provides curated resources for rapid pre-assessment, on-demand chat and discreet, personalized access to care for students on or off-campus. The innovative patient portal aims to improve and strengthen how schools offer health care solutions to their student population while reducing any potential interruptions of academic and athletic pursuits by making it possible for students to conveniently access care from anywhere. In addition, the offering eliminates social stigma and other access obstacles for students who are at-risk or potentially at-risk, making it more likely that students will avail themselves of treatment options and remain in school. These services are currently licensed to operate in Delaware, New Jersey, Pennsylvania and Maryland. Applications for licenses are underway in other states. ChristianaCare has long been a trailblazer in virtual health. Among its achievements, during the COVID-19 pandemic, ChristianaCare developed a COVID-19 virtual monitoring program that helped 37 companies in 14 states safely reopen with daily symptom monitoring, testing and connections to care for more than 10,000 employees. It’s Center for Virtual Health makes receiving care radically convenient, offering a full continuum of virtual care delivery programs. These programs include virtual primary care, specialty care programs and a Hospital Care at Home Program bringing hospital level of care to a patient’s home. The Center for Virtual Health cares for thousands of patients using state-of-the-art virtual care capabilities supporting patients in receiving care anytime, anyplace, including in the comfort of their own homes. For more information about the program, visit StudentCareSolutions.com.
Looking for a 'real' expert to explain the latest advances in virtual reality? We're here to help!
Virtual reality is quickly becoming an actual necessity in all facets of technology, education, entertainment and the workplace. It's a popular topic, and Augusta University's Lynsey Steinberg sat down to answer a few questions about how far VR has come and where it's going. VR is changing everyday life for many. What are the biggest advances you've seen in VR use? Virtual reality is rapidly evolving and expanding. It wasn’t too long ago we were excited for the idea of a wireless head set. Now there are companies such as Virtuix creating 360-degree treadmills to interact with your experience in VR and Hypnos VR (a product which releases scents in the air based on the experience in VR). There have been advances of adaptive and stress response simulations based on pupillometry measurements or even integration of physiological sensors for behavioral research. The biggest advancements are solutions that have been unimaginable before that are now entirely possible. It seems the medical field has been a big benefactor of VR. Is this giving students a better way to "learn" about anatomy and other aspects of the field? I believe all experience is valuable to learning. VR is unique in allowing an individual to view as if from their own perspective for virtual experiential learning. We often hear the phrase, “If you could imagine walking a mile in someone else’s shoes,” and now we can provide perspective, allowing another person to view the world as someone with a particular disease or simulate training in a low-risk environment. One example, Fire in the OR, is a VR simulation allowing medical professionals to train safely on how to remove fire danger in the operating room. I believe simulations like these are remarkable examples of how valuable VR can be in education, to remove elements of danger in everyday life. Their research showed 250% improvement rate on fire safety in the OR. A huge industry leader in surgical simulations is Osso VR, creating surgical training procedures for surgeons and hiring some of our Augusta University medical illustration graduates. How is this being applied at Augusta University? The Center for Instructional Innovation created modules with the Medical College of Georgia on handwashing hygiene health and end-of-life care scenarios with the College of Nursing. We encourage faculty to develop multiple methods of interactive modules for the benefit of all learning styles. VR certainly provides engaging and enriching materials for a low-risk environment in instruction. The Center for Instructional Innovation is currently working with the Academic Student Success Center to implement Oculus Quest head sets for anatomy and physiology students to benefit from application use in VR. Augusta University student Henry Oh and his 3D printed pottery from VR sculpture. How else has VR and its use changed the way we go about our daily lives? VR head sets are known in robotics, manufacturing, therapeutic modalities, gaming capabilities, technology in research and education. Any scene you can film in 360 degrees you can now watch in a headset and be fully immersed in the scene (ie: a theater production, a museum tour, an art exhibit, a temple historically preserved, etc). We have gone from telling a story to being immersed in a story. We have been able to utilize VR technology integration and innovation on campus to create enriching learning experiences. We collaborated with our Ceramics department (with Brian McGrath and Raoul Pachecho) to support students in virtual clay sculpting with Adobe Medium. Students 3D printed their works of art after exporting the files from the VR simulation. Where do you see the future of VR? The future developments for integrating systems for haptic feedback will be remarkable integrations. The continued development of behavioral research and integration of gamification is an exciting opportunity in VR as well as the continued development for protocols and appropriate safety procedures. The cross-platform and cross-disciplinary possibilities will allow for creativity to blossom in new world solutions. It is clear, the ongoing need for technical workforce required to create and support more VR and other high-impact technology is rapidly growing. VR is a fascinating topic and if you're a journalist looking to know more by speaking with Steinberg, then let us help. Steinberg is one of the 300 board-certified medical illustrators with experience in hands-on surgery in the operating room, utilizing development in virtual reality, 3D printing, animation, gamification and graphic design while working directly with students, faculty and physicians. Steinberg is available to speak with media -- simply click on her icon now to arrange an interview today.
ChristianaCare and The Wistar Institute advance partnership with new cancer research strategies
ChristianaCare’s Helen F. Graham Cancer Center & Research Institute is advancing its historic partnership with the Ellen and Ronald Caplan Cancer Center of The Wistar Institute in Philadelphia with three new research projects under way. The new research projects consist of a population health study targeting triple negative breast cancer. Other projects focus on a new therapeutic target for epithelial ovarian cancer, the most lethal gynecologic cancer in the developed world, and the development of “mini organs” derived from stem cells. Targeting triple negative breast cancer Delaware has one of the highest incidence rates of triple-negative breast cancer in the United States. This highly aggressive cancer has few treatment options, because the cells test negative for three known treatment targets – estrogen, progesterone and HER2 protein receptors. Working with patient data from the Graham Cancer Center, researchers are investigating potential contributing factors such as diet, alcohol use and genetic variants among women, and the effects of these on cancer metabolism. The team will also examine spatial relationships between cancer “hot spots”—geographic areas with a higher-than-expected prevalence—and modifiable risk factors. Key resources for the study are blood and tissue samples from the Graham Cancer Center’s Tissue Procurement Center and its statewide High-Risk Family Cancer Registry. The research team will be led by Director of Population Health Research at ChristianaCare Scott Siegel, Ph.D., and Lead Research Scientist Jennifer Sims Mourtada, Ph.D., at the Graham Cancer Center’s Cawley Center for Translational Cancer Research (CTCR). They will join Zachary Schug, Ph.D., at Wistar’s Molecular and Cellular Oncogenesis Program. Researching novel therapy for ovarian cancer The latest study supported by the Graham Cancer Center’s Tissue Procurement Program targets KAT6A expression as a novel therapy for ovarian cancer caused by a specific genetic mutation, called PP2R1A. Epithelial ovarian cancer is the most common form of ovarian cancer and the leading cause of gynecologic cancer deaths in the United States. Chemoresistance to currently available platinum-based drugs like cisplatin represents a major treatment challenge, as more than 50 percent of affected women ultimately relapse and die from this disease. Wistar’s Rugang Zhang, Ph.D., leader of the Immunology, Microenvironment and Metastases Program, is focused on developing novel therapeutics for subtypes of ovarian cancer that currently have no effective therapies and on improving the current standard of care. Dr. Zhang’s previous work suggests that KAT6A signaling plays a critical role in ovarian cancer progression. Targeting this signaling pathway could be an effective strategy for treating ovarian cancer. Working with Dr. Zhang on this project are Graham Cancer Center gynecologic oncologists Mark Cadungog, M.D., director of Robotic Surgery, and Sudeshna Chatterjee-Paer, M.D., and Cawley CTCR’s Stephanie Jean, M.D., director of Gynecologic Oncology Research. Also collaborating with the team is Wistar’s Alessandro Gardini, Ph.D., assistant professor in the Gene Expression & Regulation Program. ‘Mini organs’ offer hope for therapeutics Dr. Sims-Mourtada at the Cawley CTCR will lead a new program to culture organ-specific tissue from stem cells that could change the way diseases are studied and treated. These so called “mini organs” or “organoids” are three-dimensional tissue cultures grown in the lab that replicate the complexity and functions of a specific tissue or organ found in the body. Organoids offer scientists a better model for how drugs and other therapeutics might interact with a patient’s particular type of tumor, opening new avenues for precision medicine. “The ability to grow each patient’s tumor in a three-dimensional organoid along with our capability to create patient-derived xenograft or animal models as part of our PDX core, will allow us to fully capture the effects of genetic as well as gene altering behavioral and environmental influences that are lacking in current research models,” said Dr. Sims-Mourtada. “Our collaboration with Wistar to build these programs raises our clinical platform to the next level for studying new cancer biomarkers and treatments.” Advancing a Pioneering Partnership The Graham Cancer Center made history when it signed a first-of-its-kind agreement in 2011 with The Wistar Institute, pairing a National Cancer Institute, NCI-designated basic research institution with a community cancer center that is also an NCI Community Oncology Research Program (NCORP). “Our partnership with Wistar has attracted national recognition as a model of collaboration that leverages cutting-edge research to benefit cancer prevention and therapy statewide,” says Nicholas J. Petrelli, M.D., Bank of America endowed medical director of ChristianaCare’s Helen F. Graham Cancer Center and Research Institute. “With Wistar, our productive collaborations over the last decade continue to drive discovery research toward clinical trials to benefit patients here at the Graham Cancer Center and in communities everywhere.” “The Graham Center has been an ideal partner in our mission,” said Dario C. Altieri, M.D., Wistar president and CEO and director of the Ellen and Ronald Caplan Cancer Center. “Our scientists at Wistar have access to clinically-annotated primary patient specimens of the highest quality. As the majority of patients at the Graham Cancer Center are treatment naïve, this collaboration affords an opportunity to conduct unique, high impact mechanistic and correlative studies that will ultimately advance important scientific discoveries that hopefully will lead to better cancer therapies.”
Bowel or fecal incontinence, according to the Mayo Clinic, “is the inability to control bowel movements, causing stool (feces) to leak unexpectedly from the rectum. Also called bowel incontinence, fecal incontinence ranges from an occasional leakage of stool while passing gas to a complete loss of bowel control. Common causes of fecal incontinence include diarrhea, constipation, and muscle or nerve damage. The muscle or nerve damage may be associated with aging or with giving birth.” Dr. Satish Rao is a seasoned gastroenterologist and an expert in digestive health, particularly the brain-gut connection. Rao, a professor of medicine at the Medical College of Georgia at Augusta University, recently offered a Q&A on the topic of fecal incontinence with the journal Gastroenterology & Hepatology. What is the prevalence of fecal incontinence in the adult population? Surveys have indicated a prevalence of approximately 9% to 10% in the United States. A recent study reported a 14% prevalence, although this study was Internet-based and, thus, may not have included many elderly patients, as they may not be as computer-savvy as younger patients. It is safe to say that one in seven Americans currently suffers from fecal incontinence. Prevalence appears to be equal in men and women, although women outnumber men almost three to one when it comes to gastroenterology clinic visits and health care-seeking. Men may be too embarrassed to bring the issue of fecal incontinence to the attention of a physician, but when asked about it, they will admit and discuss it. Also, extracting information from a patient about fecal incontinence depends on how the question is asked. Asking patients whether they have daily leakage vs whether they ever have had leakage or have had leakage in the past month will elicit different responses that a clinician may interpret differently. It is important to remember that leakage is not a physiologic event that a healthy adult should have at any time, even once a month or once a year. Not having the capacity to control bowel evacuation or having leakage unaware of its occurrence signals an abnormality. What are notable risk factors for fecal incontinence? In women, pregnancy can be a risk factor, particularly if giving birth involves pelvic tissue damage, such as injury inflicted by forceps use or the unfortunate occurrence of a significant tear. Neurologic or back injuries are other common risk factors. Also, chronic diarrhea can progress to fecal incontinence owing to severe irritation of the rectum or irritants in stool. Further, any condition that changes the ability of rectal capacity can result in fecal incontinence. These circumstances can include surgery or radiation to the rectal area. Hear from a patient and learn more about Rao's research using magnetic stimulation to treat fecal incontinence. What treatment modalities are currently available? Simple, conservative treatment consists of educating patients about fecal incontinence and instructing them to avoid precipitating events. For example, although many people love to have a meal followed by a cup of coffee and a walk, such a sequence of activities is ill-advised for an incontinent patient: the meal provokes a gastric-colonic response, coffee is a powerful colonic stimulant, and exercise also stimulates motility. This triad creates the perfect storm for a stool leakage or accident while the patient is out on the after-dinner walk. Antidiarrheal therapies can be very effective but only in approximately 15% to 20% of patients. Another treatment is biofeedback, which can correct muscle weakness using behavioral techniques. Biofeedback provides resolution in approximately 50% to 70% of patients. The traditional model of office-based biofeedback requires that the patient make 6 or even up to 10 visits to a specialty clinic. This may mean that some patients must drive very long distances to an appropriate care facility that is staffed with trained personnel or physical therapists. This scenario presents a significant challenge for many patients, which is increasingly being recognized by health care professionals and researchers. Good devices for home-based biofeedback have been scarce; however, such a device was recently approved by the US Food and Drug Administration. The research center at Augusta University has tested it in a clinical trial setting and found it to be quite effective as a home biofeedback treatment. Dextranomer is another treatment modality. It involves injection of small beads of dextran polymers into the anorectal region. The beads form a protective cuff or a buffer to stop stool leakage. Another treatment modality is sacral nerve stimulation using the Medtronic InterStim system. The patient is outfitted with a pacemaker-like device with wires that continuously stimulate the sacral nerves that control stool events. In the case of a torn muscle, suturing the torn ends to reduce the size of the anorectal opening is usually useful for women postpartum, although the effect may not be sustained in the long term. What emerging treatments and research should clinicians be aware of? One emerging treatment developed at Augusta University’s Clinical Research Center is called translumbosacral neuromodulation therapy (TNT). TNT is similar to TAMS and involves the fecal delivery of magnetic energy through an insulated coil to the lumbosacral nerves that regulate anorectal function. The pulses generated are of the same strength as those of magnetic resonance imaging. The team at Augusta University’s research center has shown that TNT mechanistically improves nerve function and substantively improves stool leakage. A sham-controlled study and long-term study are currently underway at Augusta University and Harvard University’s Massachusetts General Hospital. These studies are being sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases. A multicenter study sponsored by the National Institutes of Health that the team at Augusta University also is involved with is the FIT (Fecal Incontinence Treatment) trial. This randomized study compares biofeedback with dextranomer injection. Also, as mentioned, tools are becoming available for home biofeedback that should allow many more affected patients to receive treatment because they can do so in the comfort of their own home. The research center at Augusta University is working on a novel home biofeedback protocol for the treatment of constipation and fecal incontinence. Thus, novel noninvasive tools are emerging for fecal incontinence. The repertoire of current and emerging tools holds the promise of improved outcomes for patients with fecal incontinence. Rao is also the founder of the Augusta University Digestive Health Center. He is available to speak to media regarding any aspect of digestive health -- simply click on his icon now to arrange an interview today.
ChristianaCare’s renowned Center for Heart & Vascular Health has earned the highest quality rating—three stars—from the Society of Thoracic Surgeons (STS) for its patient care and outcomes in isolated coronary artery bypass grafting (CABG) procedures. The prestigious three-star rating places ChristianaCare among the elite health care organizations for heart bypass surgery in the United States and Canada. The STS star rating system is one of the most sophisticated and highly regarded overall measures of quality in health care, rating the benchmarked outcomes of cardiothoracic surgery programs across the United States and Canada. The star rating is calculated using a combination of quality measures for specific procedures performed by an STS Adult Cardiac Surgery Database participant. “Earning a three-star rating for heart bypass surgery places us among the top heart hospitals in the nation,” said Ray Blackwell, M.D., the W. Samuel Carpenter Chief of Cardiac Surgery at ChristianaCare. “Delaware residents can be confident that they have one of the best heart surgery teams in the nation right here, close to home, at ChristianaCare.” The three-star rating from STS adds to ChristianaCare’s long list of awards for quality heart care. For the past two years, the Center for Heart & Vascular Health has earned the designation HeartCARE Center National Distinction of Excellence from the American College of Cardiology for its commitment to high quality cardiovascular care. In addition, the Center for Heart & Vascular health received the American Heart Association’s 2021 Mission: Lifeline Gold Quality Achievement Award for the treatment of patients who suffer severe heart attacks; the 2021 Get With The Guidelines NSTEMI Silver Award for patients with a less severe form of heart attack; and the 2021 Get With The Guidelines Gold Plus Award for Heart Failure. “Our Center for Heart & Vascular Health and our community have much to be proud of,” said Kirk Garratt, M.D., medical director of the Center for Heart & Vascular Health. “We provide great outcomes, and we also listen to patients and families and work to ensure that the stressful experience of surgery is as easy as it can be. That kind of commitment leads to this kind of recognition.” Heart Disease Remains a Leading Killer in the U.S. According to the American Heart Association (AHA), heart disease remains a leading killer in the nation—claiming more than 600,000 lives each year. In addition, the AHA anticipates the effects of COVID-19 are likely to influence cardiovascular health and mortality rates for many years. “February is American Heart Month, and there is no better time for us to take stock of our heart health than now,” Dr. Garratt said. “The COVID-19 pandemic has presented new challenges to people living with chronic conditions such as heart disease. People with heart conditions are at greater risk of complications from the virus and also continue to need assistance managing their heart health. If you are a heart patient, please do not postpone your regular visit with your cardiologist.” The STS is a not-for-profit organization that represents more than 7,600 surgeons, researchers and allied health care professionals worldwide who are dedicated to ensuring the best possible outcomes for surgeries of the heart, lung and esophagus, as well as other surgical procedures within the chest. The STS National Database was established in 1989 as an initiative for quality improvement and patient safety among cardiothoracic surgeons. “The Society of Thoracic Surgeons congratulates STS National Database participants who have received three-star ratings,” said David Shahian, M.D., chair of the Task Force on Quality Measurement. “Participation in the Database and public reporting demonstrates a commitment to quality improvement in health care delivery and helps provide patients and their families with meaningful information to help them make informed decisions about health care.” About the Center for Heart & Vascular Health ChristianaCare’s Center for Heart & Vascular Health is among the largest, most capable regional heart centers on the East Coast. It is one of the only centers in the region that integrates in a single location and under one roof cardiac surgery, vascular surgery, vascular interventional radiology, cardiology and interventional nephrology. Its team of experienced cardiovascular surgeons and heart experts perform nearly 700 open-heart procedures each year and treat more than 8,000 total heart and vascular cases annually. For more information, visit https://christianacare.org/services/heart/.
It was a tragic day in America this week as a 15-year-old is in custody after allegedly opening fire on a school in Oxford, Michigan, which left three teenagers dead and at least eight more wounded by the gunfire. Three students were killed in the attack at the school some 40 miles north of downtown Detroit -- Madisyn Baldwin, 17; Tate Myre, 16; and Hana St. Juliana, 14, authorities said. Myre died in a patrol car while a deputy was taking him to a hospital, Bouchard said. Eight others -- seven students and a teacher -- were shot, Bouchard said. Two were in critical condition Wednesday morning, he said. Among the wounded were a 14-year-old girl who was on a ventilator following surgery, Bouchard said Tuesday night. A 14-year-old boy also had a gunshot wound to the jaw and head, while the teacher who was shot had been discharged. The attack was the deadliest US school shooting since eight students and two teachers were slain in May 2018 at Texas' Santa Fe High School, according to Education Week. There have been 28 school shootings this year -- 20 since August 1 -- by its tally. December 01 - CNN Many are wondering how students, teachers, first responders and families grapple with incidents with this level of trauma and horror. If you are a reporter looking to cover the issues survivors of mass-shooting events might face, then let us help. Dr. Laura Wilson is a clinical psychologist whose expertise focuses on post-trauma functioning, particularly in survivors of sexual violence or mass trauma (e.g., terrorism, mass shootings, combat). Her research interests extend to predictors of violence and aggression, including psychophysiological and personality factors, as well as indicators of PTSD following mass trauma, long-term functioning among first responders, outcomes among survivors of sexual violence and the influence of media on mental illness stigma. Dr. Wilson is available to speak with media, simply click on her icon to arrange an interview today.
Head of School of Optometry named world expert in contact lenses
Professor James Wolffsohn, head of the School of Optometry at Aston University has been named by Expertscape as a world expert in contact lenses research based on his publications. Expertscape's PubMed-based algorithms placed professor Wolffsohn in the top 0.1 per cent of scholars writing about contact lenses over the past 10 years. He is also ranked by the same organisation as a world expert in presbyopia (the loss of eye focus with age affecting near vision), and is one of the top three scholars in the world. Expertscape is designed to help find the most knowledgeable physicians and health professionals in the world. Expertscape objectively ranks people and institutions by their expertise in more than 27,000 biomedical topics. James’ research focuses of the development, enhancement and validation of ophthalmic instrumentation to optimise contact lens comfort and fitting. He is also pioneering the use of contact lenses as a treatment for dry eyes; and developing methods to restore more natural eye focus through intraocular lenses, that are implanted into the eye as part of cataract surgery; as well as pharmaceutical approaches. Professor James Wolffsohn said: “I am delighted that our research in the field of contact lenses and presbyopia has had the desired impact and is widely read and cited. “Working together with colleagues in industry, we are able to accelerate product innovation, development and validation, leading to enhanced quality of life in patients.” James has published over 280 peer reviewed academic papers and given numerous international presentations. His main research areas are the development and evaluation of ophthalmic instrumentation, contact lenses, intraocular lenses and the tear film. A contact lens is a corrective, cosmetic, or therapeutic lens usually placed on the cornea of the eye. Contact lenses usually serve the same corrective purpose as conventional glasses, but are lightweight and virtually invisible. It has been estimated that about 125 million people use contact lenses worldwide. Presbyopia is the loss of eye focus with age which is usually noticed by ~45 years of age when reading glasses or another form of refractive correction is needed. It has a marked emotional effect being one of the first apparent signs of ageing.
Ray A. Blackwell, M.D., MJ, chief of Cardiac Surgery and the W. Samuel Carpenter, III, Distinguished Chair of Cardiovascular Surgery at ChristianaCare, received the 2021 Tilton Award from the Medical Society of Delaware on Oct. 28 at the Tilton Mansion, now the University & Whist Club in Wilmington, Del. The award recognizes Dr. Blackwell as a pre-eminent cardiac surgeon the past 21 years and for his life-long commitment to service for the betterment of patients, the local community and the nation. The award is named for James Tilton, M.D., the first U.S. Army Surgeon General of the United States and the first president of the Medical Society of Delaware. “Dr. Blackwell is an outstanding choice for this prestigious award,” said Kirk Garratt, M.D., medical director of ChristianaCare’s Center for Heart & Vascular Health. “He has given a great deal to his patients, his colleagues and his profession. His strong leadership and clinical expertise have led to optimal health and an exceptional experience for many patients in our community. In addition to being an excellent surgeon, Dr. Blackwell has been dedicated to driving innovations that improve patient outcomes and has been committed to finding ways of keeping patients healthy and preventing cardiovascular disease.” Since joining ChristianaCare in 1996, Dr. Blackwell has been recognized among the top cardiac physicians in our region and has been instrumental to the development of the cardiac surgery program. In 2011, he became the surgical director of the Mechanical Circulatory Support Program and led the initiative to establish Christiana Care’s Ventricular Assist Device Program. In 2017 he was named Chief of Cardiac Surgery and has since led the health system’s team of highly skilled and experienced heart surgeons who perform more than 700 heart surgeries each year. Dr. Blackwell is a clinical assistant professor of Surgery at Sidney Kimmel Medical College of Thomas Jefferson University. He served as the chair of ChristianaCare’s Blood Pressure Ambassador Advisory Committee. Dr. Blackwell has dedicated his life to service of others, especially on behalf of underprivileged and underrepresented people. As a high school student, he participated in A Better Chance Program, which places underprivileged, underrepresented and underfunded students in better academic environments. He is still active with the organization. He also served on the minority admissions subcommittee and later became a regional recruiter for Dartmouth College and Dartmouth Medical School. In 2019, he received a lifetime achievement award as part of a Dartmouth College celebration, “Standing at the Threshold,” honoring Dr. Martin Luther King Jr. Dr. Blackwell also received the Raising Kings award in 2018 from the One Village Alliance, an agency dedicated to elevating positive images and setting high expectations for Wilmington’s Black men and boys, He is a regional alumni council member of National Medical Fellowships, which funds underrepresented and underfunded medical students and is co-founder of the Association of Black Cardiovascular and Thoracic Surgeons, which supports and develops upcoming and practicing cardiothoracic surgeons. He has also held numerous leadership board positions for Delaware organizations, including the Delaware Medical Education Foundation, the Delaware Board of Medical Licensure and Discipline, the New Castle County and Great Rivers Affiliate Boards of Directors for the American Heart Association. He is also a board member of the Friends of Hockessin Colored School 107C and Indoor Track Delaware. Dr. Blackwell is also a recipient of the James H. Gilliam, Jr. Award from the American Heart Association for his contributions to the health, welfare and benefit of the community.